QTRX Quote, Financials, Valuation and Earnings

Electromed has a net margin of -34.09% compared to Quanterix's net margin of 12.11%. Quanterix's return on equity of -11.35% beat Electromed's return on equity of 15.91%.

Quanterix has a consensus price target of $12.13, signalling upside risk potential of 126.64%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 65.33%. Given that Quanterix has higher upside potential than Electromed, analysts believe Quanterix is more attractive than Electromed.

Quanterix has a beta of 1.116, which suggesting that the stock is 11.641% more volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $34.1M, which are larger than Electromed quarterly revenues of $16.3M. Quanterix's net income of -$11.6M is lower than Electromed's net income of $2M. Notably, Quanterix's price-to-earnings ratio is -- while Electromed's PE ratio is 29.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 1.52x versus 3.36x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Hologic has a net margin of -34.09% compared to Quanterix's net margin of -1.73%. Quanterix's return on equity of -11.35% beat Hologic's return on equity of 11.45%.

Quanterix has a consensus price target of $12.13, signalling upside risk potential of 126.64%. On the other hand Hologic has an analysts' consensus of $67.96 which suggests that it could grow by 27.96%. Given that Quanterix has higher upside potential than Hologic, analysts believe Quanterix is more attractive than Hologic.

Quanterix has a beta of 1.116, which suggesting that the stock is 11.641% more volatile than S&P 500. In comparison Hologic has a beta of 0.544, suggesting its less volatile than the S&P 500 by 45.552%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Hologic pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $34.1M, which are smaller than Hologic quarterly revenues of $1B. Quanterix's net income of -$11.6M is higher than Hologic's net income of -$17.4M. Notably, Quanterix's price-to-earnings ratio is -- while Hologic's PE ratio is 22.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 1.52x versus 3.07x for Hologic. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis has a net margin of -34.09% compared to Quanterix's net margin of -63.22%. Quanterix's return on equity of -11.35% beat Nuwellis's return on equity of -800.59%.

Quanterix has a consensus price target of $12.13, signalling upside risk potential of 126.64%. On the other hand Nuwellis has an analysts' consensus of $13.00 which suggests that it could grow by 1282.08%. Given that Nuwellis has higher upside potential than Quanterix, analysts believe Nuwellis is more attractive than Quanterix.

Quanterix has a beta of 1.116, which suggesting that the stock is 11.641% more volatile than S&P 500. In comparison Nuwellis has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.478%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $34.1M, which are larger than Nuwellis quarterly revenues of $2.3M. Quanterix's net income of -$11.6M is lower than Nuwellis's net income of -$1.5M. Notably, Quanterix's price-to-earnings ratio is -- while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 1.52x versus 0.17x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging has a net margin of -34.09% compared to Quanterix's net margin of -0.15%. Quanterix's return on equity of -11.35% beat Varex Imaging's return on equity of -8.27%.

Quanterix has a consensus price target of $12.13, signalling upside risk potential of 126.64%. On the other hand Varex Imaging has an analysts' consensus of $21.20 which suggests that it could grow by 156.66%. Given that Varex Imaging has higher upside potential than Quanterix, analysts believe Varex Imaging is more attractive than Quanterix.

Quanterix has a beta of 1.116, which suggesting that the stock is 11.641% more volatile than S&P 500. In comparison Varex Imaging has a beta of 0.617, suggesting its less volatile than the S&P 500 by 38.305%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $34.1M, which are smaller than Varex Imaging quarterly revenues of $199.8M. Quanterix's net income of -$11.6M is lower than Varex Imaging's net income of -$300K. Notably, Quanterix's price-to-earnings ratio is -- while Varex Imaging's PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 1.52x versus 0.41x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.